オレキシン受容体タイプ2治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Orexin Receptor Type 2 - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0409
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:81
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥378,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥756,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,134,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Orexin Receptor Type 2 – Pipeline Review, H2 2019
Summary

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) – Orexin receptor type 2 (Ox2R or OX2) also known as hypocretin receptor type 2, is a protein that is encoded by the HCRTR2 gene. OX2 is a G-protein coupled receptor expressed exclusively in the brain. OX2 binds both orexin A and orexin B neuropeptides. OX2 is involved in the central feedback mechanism that regulates feeding behavior.

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) pipeline Target constitutes close to 8 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Respiratory, Toxicology and Undisclosed which include indications Insomnia, Narcolepsy, Obstructive Sleep Apnea, Dementia Associated With Alzheimer’s Disease, Hypersomnia, Major Depressive Disorder, Opioid Induced Side Effects, Parkinson’s Disease, Sleep Disorders and Unspecified.

The latest report Orexin Receptor Type 2 – Pipeline Review, H2 2019, outlays comprehensive information on the Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)
- The report reviews Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) – Overview
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) – Companies Involved in Therapeutics Development
Eisai Co Ltd
Idorsia Pharmaceutical Ltd
Inexia Ltd
Johnson & Johnson
Takeda Pharmaceutical Co Ltd
Yangtze River Pharmaceutical Group
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) – Drug Profiles
lemborexant – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nemorexant – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OPN-021 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seltorexant – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
suvorexant – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-925 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-994 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YNT-185 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YZJ-1139 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) – Dormant Products
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) – Discontinued Products
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) – Product Development Milestones
Featured News & Press Releases
Dec 10, 2019: Eisai presents new findings on Lemborexant as potential Sleep-Wake disorder therapy at 12th Clinical Trials on Alzheimer’s Disease (CTAD) conference
Dec 02, 2019: Eisai to present latest data on lemborexant at 12th Clinical Trials on Alzheimer’s Disease Conference
Nov 22, 2019: A sleeping pill that doesn’t make you sway: a new targeted insomnia treatment
Oct 24, 2019: Trial to test insomnia drug for alcohol use disorder
Oct 01, 2019: Minerva Neurosciences announces update on Seltorexant
Sep 27, 2019: Three new analyses of data expand understanding of the potential role for investigational agent Lemborexant in Insomnia and Irregular Sleep-Wake Rhythm Disorder
Sep 26, 2019: New data presented on TAK-994, an oral selective OX2R agonist at World Sleep Congress
Sep 26, 2019: New data presented at World Sleep Congress demonstrate early signs of efficacy for TAK-925,, a selective orexin type-2 receptor (OX2R) agonist, in patients with narcolepsy type 1
Sep 19, 2019: Eisai to present latest data on Lemborexant at World Sleep Congress
Jul 11, 2019: Latest data on Eisai’s lemborexant to be presented at Alzheimer’s Association International Conference (AAIC) 2019
Jun 24, 2019: Minerva Neurosciences announces achievement of primary and key secondary objectives in phase 2b clinical trial of Seltorexant (MIN-202) in Insomnia
Jun 23, 2019: Minerva Neurosciences to host live conference call and webcast with Key Opinion Leaders to discuss successful insomnia trial with Seltorexant
Jun 13, 2019: Efficacy and safety data with Idorsias dual orexin receptor antagonist presented at SLEEP 2019 in San Antonio
Jun 11, 2019: Extensive analyses of phase 3 data for investigational Lemborexant assess efficacy and safety profile for the potential treatment of insomnia in adults
May 28, 2019: Eisai to present eight Lemborexant posters at SLEEP 2019 meeting, Including new pooled analyses from phase 3 studies and new phase 1 data
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Eisai Co Ltd, H2 2019
Pipeline by Idorsia Pharmaceutical Ltd, H2 2019
Pipeline by Inexia Ltd, H2 2019
Pipeline by Johnson & Johnson, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Pipeline by Yangtze River Pharmaceutical Group, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019

【掲載企業】

Eisai Co Ltd
Idorsia Pharmaceutical Ltd
Inexia Ltd
Johnson & Johnson
Takeda Pharmaceutical Co Ltd
Yangtze River Pharmaceutical Group

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[オレキシン受容体タイプ2治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆